Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Portugal / NCT07380087
Starting soon Not applicable

Suprascapular Nerve Block to Improve Tolerance and Outcomes of Shoulder Hydrodistension in Adhesive Capsulitis

NCT07380087 · tracked via the Priya Life Science Portugal tracker
Sponsor
Universidade do Porto
Phase
Not applicable
Started
2026-03-01
Last updated
2026-02-02

Condition(s) studied

Adhesive CapsulitisAdhesive Capsulitis of Unspecified ShoulderAdhesive Capsulitis, ShoulderFrozen ShoulderShoulder PainShoulder Stiffness

Investigational drug(s) / intervention(s)

Shoulder Hydrodistentionsuprascapular nerve block

Shoulder Hydrodistention: Shoulder hydrodistension is performed using an anterior intra-articular approach. The procedure consists of an injection of 20 mL of normal saline, 4 mL of ropivacaine, and 40 mg of methylprednisolone into the glenohumeral joint, with the aim of capsular distension, pain reduction, and improvement of shoulder mobility.

suprascapular nerve block: The suprascapular nerve block is performed under ultrasound guidance at the suprascapular notch using an injection of 2 mL of ropivacaine. The block is administered immediately before shoulder hydrodistension with the aim of reducing procedural pain and improving patient tolerance.

Study summary

Adhesive capsulitis ("frozen shoulder") causes significant pain and loss of shoulder mobility. Shoulder hydrodistension is an established treatment that can improve movement and reduce symptoms, but the procedure itself may be painful and difficult for some patients to tolerate.

This randomized clinical trial will evaluate whether performing a suprascapular nerve block with local anesthetic immediately before hydrodistension can reduce pain during the procedure, improve patient comfort, and potentially enhance clinical outcomes.

Participants will be randomly assigned to one of two groups:

hydrodistension alone, or

suprascapular nerve block followed by hydrodistension.

Pain, shoulder mobility, functional ability, psychological measures, and quality of life will be assessed at baseline, 1 month, and 3 months after the procedure. The study aims to determine whether adding a suprascapular nerve block provides better tolerability and improved recovery for patients with adhesive capsulitis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria * Adults aged 18 years or older * Clinical diagnosis of adhesive capsulitis of the shoulder * Persistent pain and functional limitation despite initial conservative treatment * Ability to understand study procedures * Ability to provide written informed consent Exclusion Criteria * Known allergy or hypersensitivity to ropivacaine or methylprednisolone * Active infection (local or systemic) * Uncontrolled coagulopathy or ongoing therapeutic anticoagulation * Recent surgery of the affected shoulder * Neurological disease affecting the upper limb * Pregnancy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Unidade Local de Saude São João, EPE Porto Porto District

More Universidade do Porto trials in Portugal

E-Mergir: A Digital Psychosexual Intervention for the Promotion of Mental and Sexual Health of Prostate Cancer Survivors Recruiting
Immediate Restoration of a New Implant With High Primary Stability Starting soon
Exercise Impact in Elderly With Multimorbidity: HbA1c and Blood Pressure Active, not recruiting
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Starting soon
Screening Coronary Artery Disease Using artiFicial intelligencE in Non-contrast Computed Tomography Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07380087 on ClinicalTrials.gov ↗ ← All trials in Portugal